Isolation of positive modulator of glucagon-like peptide-1 Signaling from trigonella foenum-graecum (Fenugreek) seed

Journal of Biological Chemistry

Volumn 290, Issue 43, 2015, Pages 26235-26248

  King, Klim ^a   Lin, Nai Pin ^b   Cheng, Yu Hong ^a   Chen, Gao Hui ^a   Chein, Rong Jie ^b  

^a ACADEMIA SINICA   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

ANTI DIABETICS; DRUG SAFETY; DRUG SCREENING; EDIBLE PLANTS; GLUCAGON-LIKE PEPTIDE-1; TRIGONELLA FOENUM-GRAECUM;

PEPTIDES;

BETA ARRESTIN; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; N 55; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE; PLANT EXTRACT;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG STRUCTURE; ENDOCYTOSIS; FENUGREEK; INSULIN RELEASE; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLANT SEED; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; CELL LINE; CHEMISTRY; DRUG EFFECTS; EMBRYOLOGY; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TRIGONELLA;

CELL LINE; GLUCAGON-LIKE PEPTIDES; HUMANS; PLANT EXTRACTS; SEEDS; SIGNAL TRANSDUCTION; TRIGONELLA;

EID: 84944916912     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.672097     Document Type: Article

References (50)

1. Campbell, J. E., and Drucker, D. J. (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837.
2. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., and Foltynie, T. (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344.
3. Hölscher, C. (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41.
4. Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E., Helqvist, S., Saunamäki, K., Terkelsen, C. J., Schoos, M. M., Køber, L., Clemmensen, P., Treiman, M., and Engstrøm, T. (2012) Exenatide reduces final infarct size in patients with ST-segmentelevation myocardial infarction and short-duration of ischemia. Circ. Cardiovasc. Interv. 5, 288-295.
5. Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., and Colao, A. (2014) GLP-1: benefits beyond pancreas. J. Endocrinol. Invest. 37, 1143-1153.
6. Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., Porter, L., and DURATION-1 Study Group. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372, 1240-1250.
7. Nauck, M. A. (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124, S3-S18.
8. Drucker, D. J. (2006) The biology of incretin hormones. Cell Metab. 3, 153-165.
9. Meier, J. J. (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742.
10. Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., and Gallwitz, B. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662.
11. Gu, G., Roland, B., Tomaselli, K., Dolman, C. S., Lowe, C., and Heilig, J. S. (2013) Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J. Comp. Neurol. 521, 2235-2261.
12. Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., and Meier, J. J. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54, 10-18.
13. Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., and Knop, F. K. (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56, 965-972.
14. Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., and Jørgensen, M. E. (2015) GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: The ADDITION-PRO Study. Diabetes 64, 2513-2525.
15. Lovshin, J. A., and Drucker, D. J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5, 262-269.
16. Butler, P. C., Elashoff, M., Elashoff, R., and Gale, E. A. (2013) A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36, 2118-2125.
17. Pierce, K. L., and Lefkowitz, R. J. (2001) Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2, 727-733.
18. Widmann, C., Bürki, E., Dolci, W., and Thorens, B. (1994) Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines. Mol. Pharmacol. 45, 1029-1035.
19. Cheng, Y. H., Ho, M. S., Huang, W. T., Chou, Y. T., and King, K. (2015) Modulation of glucagon-like peptide-1 (GLP-1) potency by endocannabinoid- like lipids represents a novel mode of regulating GLP-1 receptor signaling. J. Biol. Chem. 290, 14302-14313.
20. Haber, S. L., and Keonavong, J. (2013) Fenugreek use in patients with diabetes mellitus. Am. J. Health Syst. Pharm. 70, 1196.
21. Belaïd-Nouira, Y., Bakhta, H., Samoud, S., Trimech, M., Haouas, Z., and Ben Cheikh, H. (2013) A novel insight on chronic AlCl3 neurotoxicity through IL-6 and GFAP expressions: modulating effect of functional food fenugreek seeds. Nutr. Neurosci. 16, 218-224.
22. Al-Okbi, S. Y. (2014) Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis. Toxicol. Ind. Health 30, 738-749.
23. Bae, M. J., Shin, H. S., Choi, D. W., and Shon, D. H. (2012) Antiallergic effect of Trigonella foenum-graecum L. extracts on allergic skin inflammation induced by trimellitic anhydride in BALB/c mice. J. Ethnopharmacol. 144, 514-522.
24. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (1999) Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 274, 32248-32257.
25. Hudson, C. C., Oakley, R. H., Sjaastad, M. D., and Loomis, C. R. (2006) High-content screening of knownGprotein-coupled receptors by arrestin translocation. Methods Enzymol. 414, 63-78.
26. Córdova, A., Notz, W., Zhong, G., Betancort, J. M., and Barbas, C. F. 3rd (2002) A highly enantioselective amino acid-catalyzed route to functionalized α-amino acids. J. Am. Chem. Soc. 124, 1842-1843.
27. Gallwitz, B., Witt, M., Fölsch, U. R., Creutzfeldt, W., and Schmidt, W. E. (1993) Binding specificity and signal transduction of receptors for glucagon- like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J. Mol. Endocrinol. 10, 259-268.
28. Göke, R., Göke, B., Richter, G., and Arnold, R. (1988) The entero-insular axis: The new incretin candidate glucagon-like peptide-1(7-36)amide (GLP-1(7-36))amide. Z. Gastroenterol. 26, 715-719.
29. Fu, Z., Gilbert, E. R., and Liu, D. (2013) Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr. Diabetes Rev. 9, 25-53.
30. Andersen, N. H., Brodsky, Y., Neidigh, J. W., and Prickett, K. S. (2002) Medium-dependence of the secondary structure of exendin-4 and glucagon- like-peptide-1. Bioorg. Med. Chem. 10, 79-85.
31. Gefel, D., Hendrick, G. K., Mojsov, S., Habener, J., and Weir, G. C. (1990) Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3', 5' -monophosphate formation. Endocrinology 126, 2164-2168.
32. Sharma, R. D. (1986) Effect of fenugreek seeds and leaves on blood glucose and serum insulin responses in human subjects. Nutr. Res. 6, 1353-1364.
33. Neelakantan, N., Narayanan, M., de Souza, R. J., and van Dam, R. M. (2014) Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: A meta-analysis of clinical trials. Nutr. J. 13, 7.
34. Madar, Z., Abel, R., Samish, S., and Arad, J. (1988) Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. Eur. J. Clin. Nutr. 42, 51-54.
35. Runge, S., Schimmer, S., Oschmann, J., Schiødt, C. B., Knudsen, S. M., Jeppesen, C. B., Madsen, K., Lau, J., Thøgersen, H., and Rudolph, R. (2007) Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 46, 5830-5840.
36. Zhang, L., and Bulaj, G. (2012) Converting peptides into drug leads by lipidation. Curr. Med. Chem. 19, 1602-1618.
37. Ward, B. P., Ottaway, N. L., Perez-Tilve, D., Ma, D., Gelfanov, V. M., Tschöp, M. H., and Dimarchi, R. D. (2013) Peptide lipidation stabilizes structure to enhance biological function. Mol. Metab. 2, 468-479.
38. Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., and Johansen, N. L. (2007) Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 50, 6126-6132.
39. Koole, C., Wootten, D., Simms, J., Valant, C., Sridhar, R., Woodman, O. L., Miller, L. J., Summers, R. J., Christopoulos, A., and Sexton, P. M. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway- selective manner: implications for drug screening. Mol. Pharmacol. 78, 456-465.
40. Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X., Cox, A. L., Michael, M. D., Gutierrez Sanfeliciano, S. M., Tebbe, M. J., and Coghlan, M. J. (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59, 3099-3107.
41. Nolte, W. M., Fortin, J. P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., and Carpino, P. A. (2014) A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat. Chem. Biol. 10, 629-631.
42. Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., Jorgensen, A. S., Kercher, T., Kostrowicki, J., Madsen, P., Olesen, P. H., et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 937-942.
43. Wang, E., and Wylie-Rosett, J. (2008) Review of selected Chinese herbal medicines in the treatment of type 2 diabetes. Diabetes Educ. 34, 645-654.
44. Roberts, K. T. (2011) The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. J. Med. Food 14, 1485-1489.
45. Mathern, J. R., Raatz, S. K., Thomas, W., and Slavin, J. L. (2009) Effect of fenugreek fiber on satiety, blood glucose and insulin response and energy intake in obese subjects. Phytother. Res. 23, 1543-1548.
46. Hannan, J. M., Ali, L., Rokeya, B., Khaleque, J., Akhter, M., Flatt, P. R., and Abdel-Wahab, Y. H. (2007) Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br. J. Nutr. 97, 514-521.
47. Lu, F. R., Shen, L., Qin, Y., Gao, L., Li, H., and Dai, Y. (2008) Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin. J. Integr. Med. 14, 56-60.
48. Zhou, J., Chan, L., and Zhou, S. (2012) Trigonelline: A plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr. Med. Chem. 19, 3523-3531.
49. Uemura, T., Hirai, S., Mizoguchi, N., Goto, T., Lee, J. Y., Taketani, K., Nakano, Y., Shono, J., Hoshino, S., Tsuge, N., Narukami, T., Takahashi, N., and Kawada, T. (2010) Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol. Nutr. Food Res. 54, 1596-1608.
50. Sauvaire, Y., Petit, P., Broca, C., Manteghetti, M., Baissac, Y., Fernandez- Alvarez, J., Gross, R., Roye, M., Leconte, A., Gomis, R., and Ribes, G. (1998) 4-Hydroxyisoleucine: A novel amino acid potentiator of insulin secretion. Diabetes 47, 206-210.